Locations:
Search IconSearch

Tag: SUNBEAM

19-NEU-3979-relapsing-multiple-sclerosis-650×450
September 24, 2019/Neurosciences/Research

Phase 3 Ozanimod Trials Show Good Efficacy and Tolerability at 2 Years for Relapsing MS

Findings hint at potentially easier treatment initiation vs. other S1P receptor modulators

BackPage 1 of 1Next

Advertisement

Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy

Ad